11:54 PM EDT, 04/16/2023 (MT Newswires) -- Merck & Co. (MRK.PA) on Sunday said Keytruda combined with gemcitabine and cisplatin helped extend the lives of certain patients with biliary tract cancer in a late-stage study.
The phase 3 trial, dubbed Keynote-966, is examining Keytruda plus the standard of care chemotherapy as a first-line treatment of patients with advanced or unresectable biliary tract cancer, a rare condition in which cancer cells develop in the bile duct. Data showed a statistically significant and clinically meaningful improvement in the overall survival of patients who received the Keytruda-chemotherapy combination compared with chemotherapy alone.
The company intends to share the results of Keynote-966 with global health authorities.
Merck traded marginally higher at the close of April 14.
VIP课程推荐
APP专享直播
热门推荐
收起
24小时滚动播报最新的财经资讯和视频，更多粉丝福利扫描二维码关注（sinafinance）
